  This systematic review and meta-analysis of randomized controlled trials ( RCTs) was conducted to determine the effect of alpha-lipoic acid ( ALA) supplementation on the inflammatory markers among patients with metabolic syndrome<disease> ( MetS) and related disorders. We searched the following databases until November 2017: PubMed , MEDLINE , EMBASE , Web of Science , and Cochrane Central Register of Controlled Trials. Three reviewers independently assessed study eligibility , extracted data , and evaluated risk of bias of included primary studies. Statistical heterogeneity was assessed using Cochran 's Q test and I-square ( I Eighteen trials out of 912 potential citations were found to be eligible for our meta-analysis. The findings indicated that ALA supplementation significantly decreased In summary , the current meta-analysis demonstrated the promising impact of ALA administration on decreasing inflammatory markers such as CRP , IL-6 and TNF-Î± among patients with MetS and related disorders.